July 24 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :
* INTELLIPHARMACEUTICS INTERNATIONAL SAYS ANNOUNCES UPDATE ON ITS OXYCODONE ER NEW DRUG APPLICATION - SEC FILING
* INTELLIPHARMACEUTICS - FDA ADVISED IT “IS POSTPONING PRODUCT-SPECIFIC ADVISORY COMMITTEE MEETINGS FOR OPIOID ANALGESICS,” INCLUDING THE ONES FOR CO'S NDAS
* INTELLIPHARMACEUTICS - REASON FOR POSTPONEMENT FOR PRODUCT-SPECIFIC ADVISORY COMMITTEE MEETINGS FOR OPIOID ANALGESICS IS NOT UNIQUE TO CO'S PRODUCT
* INTELLIPHARMACEUTICS INTERNATIONAL - FDA INFORMED CO THAT IT WOULD CONTINUE TO REVIEW CO'S NDA ACCORDING TO THE EXISTING PDUFA TIMELINE
* INTELLIPHARMACEUTICS INTERNATIONAL - FDA NOTED DUE TO POSTPONEMENT OF AADPAC MEETING, IT IS POSSIBLE FDA MAY BE UNABLE TO MEET PDUFA GOAL DATE OF AUG. 28